Molbiol has been part of Roche for one year already!
Much done, more to do. This is how one could describe our current status. I am extremely proud of the team effort that lies behind us. And we move on: Our company will remain known for quick reactions to global outbreaks, flexibility regarding client requests and maximum customer proximity. To reach this goal, we will invest in staff, infrastructure and product innovation. Moving our PCR tests under the umbrella of IVDR will be our highest priority in the coming months.
It is our mission to develop high-quality PCR tests. Covid has put the value of diagnostics in the spotlight – as well as the research & development associated with it. For decades, TIB Molbiol has been delivering solutions to global and local challenges. With this legacy, TIB Molbiol’s future as part of the Roche family will be finding diagnostic solutions to fight all kinds of ailments, for example infectious diseases. In this regards, we have delivered an answer to the monkeypox-outbreak early on this year.
Best regards from Berlin
December 2022
Dr. Marcus Droege
General Manager, TIB Molbiol
